Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of HPN-100 for Maintaining Remission in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy

NCT00999167 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00999167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00999167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of HPN-100 for Maintaining Remission in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2009
Completion date
April 30, 2012
Enrollment
189 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

cirrhosis, hepatic encephalopathy